• Publications
  • Influence
Telaprevir for previously untreated chronic hepatitis C virus infection.
BACKGROUND In phase 2 trials, telaprevir, a hepatitis C virus (HCV) genotype 1 protease inhibitor, in combination with peginterferon-ribavirin, as compared with peginterferon-ribavirin alone, hasExpand
  • 2,435
  • 109
  • PDF
The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD
Patients with nonalcoholic fatty liver disease (NAFLD) and advanced liver fibrosis are at the highest risk for progressing to end‐stage liver disease. We constructed and validated a scoring systemExpand
  • 1,676
  • 100
  • PDF
IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy
Hepatitis C virus (HCV) infects 3% of the world's population. Treatment of chronic HCV consists of a combination of PEGylated interferon-α (PEG-IFN-α) and ribavirin (RBV). To identify geneticExpand
  • 1,849
  • 95
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
NAFLD is one of the most important causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming decades, with the disease affecting bothExpand
  • 1,069
  • 50
  • PDF
NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome
Nonalcoholic steatohepatitis (NASH) is often linked with disorders that are clearly associated with insulin resistance (IR): obesity, type 2 diabetes mellitus, and hypertriglyceridemia. We tested theExpand
  • 1,055
  • 40
Animal models of nonalcoholic fatty liver disease
In 1980, Ludwig and colleagues described a series of patients with liver histology characterized by the accumulation of fat and the presence of hepatic necroinflammation in the absence of a historyExpand
  • 359
  • 35
Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection.
BACKGROUND Staging hepatic fibrosis by liver biopsy guides prognosis and treatment of hepatitis C, but is invasive and expensive. We sought to create an algorithm of serum markers that accurately andExpand
  • 498
  • 31
  • PDF
Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis
In a systematic review and meta-analysis, Giovanni Musso and colleagues examine the association between non-alcoholic fatty liver disease and chronic kidney disease. Please see later in the articleExpand
  • 320
  • 23
  • PDF
Beyond insulin resistance in NASH: TNF‐α or adiponectin?
Adiponectin has antilipogenic and anti‐inflammatory effects, while tumor necrosis factor α (TNF‐α) reduces insulin sensitivity and has proinflammatory effects. We examined (1) the extent to whichExpand
  • 785
  • 22
Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss
Weight loss remains the most common therapy advocated for reducing hepatic lipid in obesity and nonalcoholic fatty liver disease. Yet, reduction of body weight by lifestyle intervention is oftenExpand
  • 473
  • 18